Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 11/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21456788 | 0.87 | CYP2C19 (0.49) | CYP2C19PIK3C3HTR6L3MBTL1MET | |
| SCHEMBL29952621 | 0.83 | CYP2C19 (0.55) | CYP2C19PIK3C3HTR6L3MBTL1MET | |
| SCHEMBL781277 | 0.75 | MEN1 (0.49) | HTR6HTR1ADRD2 | |
| SCHEMBL12272025 | 0.73 | L3MBTL1 (0.56) | CYP2C19HTR6L3MBTL1PKM | |
| SCHEMBL29959107 | 0.72 | CYP2C19 (0.58) | CYP2C19HTR6L3MBTL1METENPP3 | |
| SCHEMBL1672537 | 0.72 | CYP2C19 (0.58) | CYP2C19HTR6L3MBTL1METPKM | |
| SCHEMBL414843 | 0.72 | CYP2C19 (0.58) | CYP2C19HTR6L3MBTL1METENPP3 | |
| SCHEMBL2086330 | 0.71 | HTR6 (0.61) | CYP2C19PIK3C3HTR6L3MBTL1MET | |
| SCHEMBL16010409 | 0.71 | NCF1 (0.37) | CYP2C19HTR1A | |
| SCHEMBL21886201 | 0.70 | L3MBTL1 (0.46) | HTR6L3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283475-B1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-10179777-B2 | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives | MERCK PATENT GMBH (DE) | 2019-01-15 | — | — | US | disclosed |
| US-20180099947-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-04-12 | — | — | US | disclosed |
| EP-3283475-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | Merck Patent GmbH (DE) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016165808-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179777-B2 | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives | ALK, ABL2, ACVR1 | CYP2C19 2699/4885PIK3C3 2641/4885HTR6 3915/4885 |
| US-20180099947-A1 | 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES | ALK, ABL2, ACVR1 | CYP2C19 2699/4885PIK3C3 2641/4885HTR6 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.